Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf4.! « » - " " . ; % " & , & , ,
" & , , # ,.
" & :
1.6
2.# (6 )
3.# "
" & & :
1.?J;
2.?J;
5.H)B $
+ :
1.@$# (30% & 10,0 % - 10-15 V ; 10% & $ 10,0 % - 10-15 V ; 10% & 10,0
% - 10-15 V ) - .
2. |
? ( % ): 25 , |
|
10 , 1 . |
|
|
3. |
$ |
: 0,1 % &, |
0,1 % &, 0,1 % &, 1 % &. + & % & &$ ( ). @ " % % " 3 "$ & & " & &$ ( -IV). $#" & $, 3 % & & 3 ", $# .
4.! ( &). " &$ 0,5 5% . " , & ," " , % &. ! & " # " 3 , %, 3 " & . !% , $& 2%, % 2- $ &$ & " " % . + & " , % & " " 3% .
5.+ & . ! & , % , ,
|
|
# . |
|
|
|
$ |
|
& , |
$# , |
, |
" , |
||||
$# . @ " |
|
$ |
|||||
5–10% |
. L & & |
||||||
, , , |
. |
|
|
||||
6.5% - &, $# $# .
7.. ? # , 3 ,. — "3 , # .
3 & . , & &$ " 3 . J "" . @ & % "&$ 3 & & ( $ 3 $), % % — 3 & ( 2 ). ,3- .
8. & , D3, ", $ " & % . & % , "$ $, % ,$# $ , & . +$ & . 6 & % & % &
100 . , . |
|
|
||
9. |
(114 , % ) |
1 % " 12 " " 1 . |
||
10. |
' " |
" |
" , , |
|
3 |
|
" - |
|
|
, |
$# " . + " : |
5 " 8 |
||
" (15 )- 1 $, 2-3 ; V 25-50 1 $-3-4 V " , " .
11. % " " &$ $. ) " & " % H_-"( ).
" & :
1.30% & ,
2.10% & $,
3.10% & ,
4.G 25 ,
5./ 10 ,
6.1 ,
7.< 0,1 % &
8.6 0,1 % &
9.; 0,1 % &
10.1 % &.
11.! 2% &
12.114 , %
13.? & 0,25 ,
" & & :
1.5% - &
2.5–10%
3.3 , ,
4.& ( &, , )
5. 6 , 2,5 ; . 0,005; 0,05 0,1
6.5 , .
7.@ 4 .
|
,- ! : |
3 " : $ 1 3 . |
|
|
: % |
, 3 . |
|
/ |
, & : |
1. |
British Association of Dermatologists guidelines for use of biological interventions in |
psoriasis 2005 C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D.
Chandler, A.Y. Finlay, C.E.M. Grifitths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds and A.D. Ormerod (Chair of Guideline Group).
2.Psoriasis. Snellman E. Psoriasis. In: EBM Guidelines. Evidence – Based Medicine. (CDROM). Helsinki, Finland: Duodecim Medical Publication Ltd.; 2004 Jun 18 (various). (74 references) www.prodigy. Nhs. U
3.@ & . >% " . L & 6. 6.6 ! , 2003 .. 1865-1867.
* – , # (% % )
: 01-118
"$ &: "
: 6!
& ! : & " & , " &
$ &, & & % & |
" , & |
|
% ( , % ), " & " % . |
|
|
' & & : & |
|
|
(:G35 |
|
|
) : (PC) - |
" , |
$# , |
$# , $# "
, $# |
" % |
|
# , |
# % . |
|
$ : |
|
|
! # $# !: |
|
|
|
# : |
|
1./ & |
|
|
2.! |
& |
|
3./ & |
|
|
"$ : |
|
|
1.$# - $# ($# ) % &;
2." ( "" " );
3. ' " ( " ); 4. - $# ( $ "$# " )
* : ' " # (20-40 ). L #$ % # . PC -
( , , , , |
), |
" |
" " &$. |
H |
|
& PC 20-50 , " # |
. |
|
: ' PC % & " |
. |
|
" " , $# -, . B PC $,, & $:
-;
-& " &$ ;-;
-% &$ ;
-.
" |
PC |
|
||||
& " ;- |
. |
|||||
|
PC $ " ;- % |
|
||||
& &, 3 |
. |
|||||
|
|
: @ PC |
, |
, |
|
|
: |
|
|
|
|
|
|
-# & " $ ( " % ); |
|
|||||
- #&$ - (6 ;); |
|
|
||||
- " . |
|
|
|
|
||
" & $# " |
|
|||||
" # /+!. |
|
|
||||
' " & & %# , & "1 " , " 2- .
+ " PC 6 ;, % & % " % /+! PC && . & 6 ;, ( " " ), $ $PC.
" & :
1.& &
2.6-
3.#
4.# "
5.< "
" & & :
1.? & %
2.&$
3.&
+ : J , $# " & ! . " PC % , &, "" & 3 & "
. J " & % "& |
" , |
||||
$# " . |
|
|
|
||
' & " ! % |
& |
– |
|||
" " . |
|
|
|
|
|
" |
" |
|
% |
|
|
. < & 3 |
– |
||||
|
, |
$ |
$, |
||
3 " & . : – $ ( ). B - - -1 ( 3 , $ & & " # " ). 0,25 (8 . 6>), % 1, % , " &. ! " & ? ? + &-1 & – ? " $#- $# "- $# PC. J " % & % & " PC " &- & . " " -& " .
! ($" & ) % " &. % & " % & : 6 /
1 " 3 - 5 $# |
|
& . |
||
' $ $ & |
1 / , |
|
||
% & |
" 1 – 2 &. + |
|||
& " ( 3 |
) |
% & |
|
|
( " 3 ). > & , & " & $.
9 :
1.! & %$ # " , $ "$# $ – " 2-3 200
400 , ( 10 , 1 3 , " 1 ,"& % 200 600 40" , " & 50,0100,0 " 5 10 V ).
2. ! " & , % " & % % " . " ""$ ( " & – 5 2-3 ; " – 20 30 / ) 50 150 / .
3." " & "" . + " % &
$ " # . + &
" , % "
|
D. @ " " " 100- |
400 |
& 10-40 & . % " |
5 15 / .
4.# & " & & .
5." & ( 50100 ; 20 )
& & " % . " "" % & & " & & .
" & :
1. *6 4 , , V 40 , 125 , 250 , 500
2.*< 8 6> % " & ( - -1 , &)
" & & :
1.*< 10 , 25 ,
2.*; 50 % , 150 V 100
3.*@ , 200 , 400
4.5 ,
5.*_ 50 ,
6.*_ 10 , 20 ,
7.*@ "& 200 , %
8. * " & , V 5, 10
9.*' 10 ,
10.* 200
11.*; 100
12.*/ 200
13. |
*; 1 5%; 10%, 50% |
||
14. |
*? V 5%, 10% 2 , 5 |
||
,- ! : |
|||
1. |
@ !; |
||
2. |
" ; |
|
|
/ |
|
, & |
: |
1. " |
$# " . 6, 2002 |
||
2." $ " " . B.+.@ , M.J.K " .6.2004
3.@ & . >% " . ' 2.2003
4.Multiple sclerosis. National clinical guideline for diagnosis and management in primary and
secondary care National
Institute for clinical excellence. 2004.
2.The use of mitoxantrone for the treatment of multiple sclerosis: report of the Therapeutics and Technology assessment
Subcommittee of the American Academy of Neurology. 2003.
3.The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in treatment of multiple sclerosis. Final outcome of the randomized controlled trial. Final outcome of the randomized controlled trial // Neurology.- 1995.- V. 45.- P. 1277-1285.
4.>.B., @ ;.J., < ?.+., G " +.'. +- // D. . . ! . : .-
2003.- 8 2.-!. 98-102.
5. Gold R. Adherence to treatment: value of patient support. Oral presentation at International Sobering Symposium. Copenhagen, 2004.
* – , # (% % )
: 05-050 |
|
|
|
|
||
|
|
|
|
|
||
"$ &: " |
|
|
|
|
|
|
: 6! |
|
|
|
|
|
|
& ! : |
|
|
|
|
|
|
1. |
% J |
" |
||||
( $). |
|
|
|
|
||
2. |
# , $# |
|
|
|||
. |
|
|
|
|
|
|
' |
& & : & «@» |
" |
& ( |
|||
" , " % |
). |
|
||||
(: |
|
|
|
|
|
|
I00 |
" " |
|||||
I01 |
" " |
|
|
|
|
|
I02 |
" |
|
|
|
|
|
I05 |
" ( |
) & |
|
|
|
|
I06 |
" ( |
) & |
|
|
|
|
I07 |
" ( |
) " |
|
|
||
I08 |
% & |
|
|
|
|
|
I09 |
@ " |
|
|
|
|
|
M79.0 "
) : - & & " " , -"?, $# " % $.
$ : ? (2003 ):
1." : " , " ;
2." :
3.: , , , & 3 , % "
4.@ & : , , & ,
5.B : ; " " & ( ,)
6.! " .
* : % , &-3 " , " &,
" |
|
% &. |
|
|
: |
1.< & - , , , & 3 , % " .
2.6 - " : , ; : " ! 7,! <; & : PQ 7 ,
& & -7 , 3. @ , %$# $#$ $ $.
4. + " & & 2- ,
$#$ '-"$ |
$ |
$ ( ?- |
|||||||
& , |
|
|
|
|
% & |
||||
?- , |
|
|
$# |
||||||
?!J-, -@+- ' & |
|||||||||
. |
|
|
|
|
|
|
|
|
|
+ " |
|
" , |
|||||||
% |
|
, |
|
" |
|
||||
% , " # |
%$ |
|
, |
|
" &, |
||||
" & % . " : 90% & , % , & 3 , , , , 3, , &-.
" & :
1.#
2.# "
3.J- - .
4..
5.# .
7.!- .
8.7
9..
10.3- # .
11.7G (@ J> 7G ).
" & &
1. < " .
+ : J " " , .
+ |
|
3 # " |
J - |
: |
|
||
1. |
@ & , |
J ( , ) – 5 ; |
|
2.@ & , J & 5 (% & 25 )
3.< & , & "
- " % .
4.? & :
5." " " & 3 .
6.? 3 # "
3 ( ?)
7.' " - D – 2,4 >@ 1 3 – " .
8., # , & :
9.? * 2 1 " & . % &
& / / 2 30
10.- *500 * 500600 .
11.% & / * 600* / / 1 .
12.% "-" & :
13.? *2 1 " & . % &
& / / * 2 30
14.* 1 / " 1-2", " & 30 .
15.: * 2,4 / 1 3 .
16.+ & (+ '!): *
17. + " |
$ % , |
|
" " : * (0,5-2 / ) % 6-12 |
||
" , " 2 $ "$ 120-160 . ) |
|
|
& |
! 7 " 1 . %$ % 2 5 . @ |
|